- Home
- TNXP vs LGI Comparison
TNXP vs LGI Comparison
Compare TNXP & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- LGI
- Stock Information
- Founded
- TNXP 2007
- LGI 2004
- Country
- TNXP United States
- LGI United States
- Employees
- TNXP N/A
- LGI N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- LGI
- Sector
- TNXP Health Care
- LGI
- Exchange
- TNXP Nasdaq
- LGI Nasdaq
- Market Cap
- TNXP 197.9M
- LGI 217.2M
- IPO Year
- TNXP N/A
- LGI N/A
- Fundamental
- Price
- TNXP $15.12
- LGI $17.37
- Analyst Decision
- TNXP Buy
- LGI
- Analyst Count
- TNXP 1
- LGI 0
- Target Price
- TNXP $70.00
- LGI N/A
- AVG Volume (30 Days)
- TNXP 778.7K
- LGI 41.1K
- Earning Date
- TNXP 11-10-2025
- LGI 01-01-0001
- Dividend Yield
- TNXP N/A
- LGI 7.10%
- EPS Growth
- TNXP N/A
- LGI N/A
- EPS
- TNXP N/A
- LGI N/A
- Revenue
- TNXP $10,299,000.00
- LGI N/A
- Revenue This Year
- TNXP $14.79
- LGI N/A
- Revenue Next Year
- TNXP $933.49
- LGI N/A
- P/E Ratio
- TNXP N/A
- LGI N/A
- Revenue Growth
- TNXP N/A
- LGI N/A
- 52 Week Low
- TNXP $6.76
- LGI $12.66
- 52 Week High
- TNXP $130.00
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- TNXP 35.51
- LGI 51.80
- Support Level
- TNXP $13.70
- LGI $16.46
- Resistance Level
- TNXP $18.25
- LGI $17.09
- Average True Range (ATR)
- TNXP 1.28
- LGI 0.37
- MACD
- TNXP 0.07
- LGI -0.01
- Stochastic Oscillator
- TNXP 26.08
- LGI 67.50
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.